ClinicalTrials.gg
CompletedNCT04591275Updated Feb 20, 2025

Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .

A Phase 3 interventional study of CMAB807 Injection and Prolia® in Postmenopausal Osteoporosis, sponsored by Shanghai Biomabs Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to female participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by Shanghai Biomabs Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
278
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.

Enrollment
16th of 31
278 · median 278
Started
2021
with 2 others
Phase 3
17 of 31
1 open now
Registered
24th of 31
by date
Lead sponsor
2 of 31
Shanghai Biomabs Pharmaceutical Co., Ltd.

Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 16th largest by enrollment, is one of 3 that started in 2021, is one of 17 in phase 3, and was the 24th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 50 Years to 85 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing denosumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

evaluate the differences in effectiveness and safety between CMAB807( potential biosimilar) and Prolia(original product)

Read the detailed description

this is a randomized, double-blinded, parallel, active-controlled clinical phase III study. the primary objective is to evaluate the efficacy and safety of CMAB807 treatment compared with Prolia in Chinese postmenopausal women with osteoporosis at high risk of fracture.

Subjects should sequentially enrolled according to the protocol in one of two arms. Subjects who entered in test arm would receive 60mg of CMAB807 subcutaneously every 6 months for one year, while those who entered in control arm should receive 60mg of Prolia subcutaneously every 6 months for one year. Meanwhile, every subject should taking 600mg calcium and 400IU vitamin D daily from successfully screening to the end of study.

03

Conditions studied

  • Postmenopausal Osteoporosis
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully informed, understood, voluntary participate, and the patient himself or guardian agree to sign the written and patient be able to comply with the protocol;
  2. Aged from 50 years to 85 years, inclusive;
  3. Spontaneous amenorrhea time ≥ 2 years, or bilateral oophorectomy≥ 2 years. If the status of bilateral ovariectomies is unknown, the menopause status should be confirmed by follicle stimulating hormone(FSH) level≥ 40IU/L;
  4. Based on the results of dual energy X-ray absorptiometry, BMD of lumbar spine(L1\~L4), femoral neck or total hip: -4.0\<T-Score≤-2.5;
  5. There must be at least one of the following risk factors:

    • History of osteoporotic fracture;
    • Father's and mother's hip fracture history, or both parents';
    • Low (≤19kg/m\^2);
    • Patient's age was equal or greater than 70 years old;
    • Current smoker;
    • CTX1 was one standard deviation higher than that of healthy premenopausal women within screening period(ie, CTX1>0.43ng/mL);
  6. Ability to act independently.

Exclusion criteria

Exclusion Criteria:

  1. Suffering from the following diseases known to affect calcium or bone metabolism:

    • Various metabolic bone diseases, such as osteogenesis imperfecta and osteomalacia;
    • Paget's osteopathy;
    • Cushing's syndrome;
    • Hyperprolactinemia;
    • Hypopituitarism;
    • Acromegaly;
    • History of hyperparathyroidism or hypoparathyroidism;
    • History of hyperthyroidism or hypothyroidism(hypothyroidism patients can be included: only receiving stable thyroid hormone replacement therapy, if the thyroid stimulating hormone(TSH) level is normal, or 5.5μIU/mL\<TSH≤10.0μIU/mL, and free thyroxine(FT4) is in normal range can be included);
    • Malabsorption syndrome or various gastrointestinal diseases associated with malabsorption, such as Crohn's disease and chronic pancreatitis;
    • Abnormal level of blood calcium: the current diagnosis of hypocalcemia or hypercalcemia or albumin corrected serum calcium levels are not within the laboratory normal range(calcium supplements should not be used for at least 8 hours prior to serum calcium testing);
    • Vitamin D deficiency: 25 hydroxyvitamin D concentration\<20ng/mL. Allowed to retest after oral vitamin D2 soft capsules in the screening period. If the concentration of 25 hydroxyvitamin D is more than or equal to 20ng/mL, it can be selected;
    • Other diseases such as rheumatoid arthritis, gout, multiple myeloma, etc;
  2. Medical history of two or more vertebrae fractures;
  3. Malignant tumor(excluding skin basal cell carcinoma or squamous cell carcinoma, cervical carcinoma in situ or breast ductal carcinoma in situ) in recent 5 years;
  4. Severe renal function damage( rate\<30mL/min), or dialysis, urinary calculi or chronic cystitis;
  5. Suffering from the following liver or biliary diseases:

    • Liver cirrhosis;
    • Biliary abnormalities(except for Gilbert syndrome or asymptomatic gallstones);
    • Positive virus antibody(HCV-Ab) and the titer of HCV-RNA exceeded the upper limit of norma;
    • Positive suface antigen(HBsAg) and peripheral blood HBV-DNA titer ≥1000 capies[CPS]/mL or 200IU/mL;
    • Unstable liver disease: defined as liver ascites, hepatic encephalopathy, coagulopathy, hypoalbuminemia, varicosis in esophagus or stomach fundus or persistent hepatic jaundice;
  6. Liver transaminase: ≥2.0×upper limit of norma value(), alanine aminotransferase≥2.0ULN, alkaline phosphatase≥1.5ULN or total ≥1.5ULN;
  7. Suffering from the following oral diseases:

    • Osteomyelitis or osteonecrosis of the jaw, previously or currently;
    • Actue dental or mandibular disease requiring stomatological surgery;
    • Planned invasive dental surgery during the trial period;
    • Dental or stomatological surgery have not healed;
  8. Conditions which can influence bone mineral density determination by dual energy X-ray absorptiometry:

    • Less than two lumbar vertebrae can be measured;
    • Height, weight or waistline may hinder accurate measurement;
    • Other conditions that may affect bone density testing
  9. Received anti-osteoporosis drugs or those drugs may affect bone metabolism:

    • Use of injectable bisphosphonates, fluoride or strontium within 2 years before screening;
    • Use of oral bisphosphonates: more than 2 years, or more than 3 months but less than 2 years and discontinued from last dosage less than 1 year, simultaneously;
    • Usage of any drugs which may affect bone metabolism within 6 weeks before screening: parathyroid hormone or parathyroid hormone analogue(such as teriparatide); assimilative hormone or testosterone; (equivalent to prednisone>5mg/day for more than 10 days); systemic hormone replacement therapy; selective estrogen receptor regulator(such as reloxifene); tibolone; calcitonin; active vitamin D and ite analogues, other bone active drugs include anticonvulsant drugs(except benzodiazepines) and he[arin; long-term systemic use of ketoconazole, androgen, adrenocorticotropic hormone, cinacalcet, aluminum, lithium, protease inhibitors, methotrexate, gonadotropin releasing hormone agonist;
    • Patients who have received RANKL inhibitors previously;
  10. Positive antibody;
  11. Known alcoholism or drug abuse(during 12 months before screening), because alcohol or drug abuse may interfere with subject's understanding or finish of trial;
  12. Known allergy to test drug, reference drug or basic drug and its ;
  13. Participate in interventionary clinical study(drug or device) within one month before screening;
  14. Other serious, acute or chronic diseases, mental disorders or laboratory abnormalities, which are judged by investigator to be unsuitable to participate this study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
278 participants (actual)

Study arms

  • Experimental
    CMAB807

    60mg, every 6 months, subcutaneously for twice. dietary supplement: elemental calcium orally, 600mg, daily, and vitamin D orally, 400IU, daily

    Drug: CMAB807 Injection

  • Active comparator
    Prolia®

    60mg, every 6 months, subcutaneously for twice. dietary supplement: elemental calcium orally, 600mg, daily, and vitamin D orally, 400IU, daily

    Drug: Prolia®

Interventions

  • mAb targeting RANKL, human monoclonal antibody targeting RANKL

    Also known as: Denosumab Injection

  • mAb targeting RANKL, human monoclonal antibody targeting RANKL

    Also known as: Denosumab Injection

06

What researchers measure

Primary outcomes

  1. BMD percentage change from baseline at lumbar spine(L1~L4)

    Percentage change from baseline at lumbar spine(L1\~L4) by dual-energy X-ray absorptiometry to month 12 of treatment and compare between two arms. Percentage change of lumbar spine BMD from baseline to at month 12 of treatment=(BMD at month 12 of treatment - BMD at baseline)/BMD at baseline\*100%

    Time frame: baseline, at 12 months

Secondary outcomes

  1. BMD percentage change from baseline at lumbar spine(L1~L4)

    Percentage change from baseline at lumbar spine(L1\~L4) by dual-energy X-ray absorptiometry to month 6 of treatment and compare between two arms. Percentage change of lumbar spine BMD from baseline to at month 12 of treatment=(BMD at month 12 of treatment - BMD at baseline)/BMD at baseline\*100%

    Time frame: baseline, at 6 months

  2. BMD percentage change from baseline at total hip, trochanter and femoral neck

    Pencentage change from baseline at total hip, trochanter and fremoral neck by dual-energy-X-ray absorptiometry to month 6 and month 12 of treatment, and compare between two arms. Percentage to total hip, trochanter and femoral neck BMD from baseline at month 6 or month 12 of treatment=(BMD at month 6 or month 12 of treatment - BMD at baseline)/BMD at baseline\*100%

    Time frame: baseline, at month 6, at month 12

  3. Serum CTX1 and P1NP concentration percentage change from baseline

    Fasting serum CTX1 and P1NP samples should be collected. Percentage changes of serum CTX1 or P1NP concentrations from baseline at month 1, month 3, month 6, month 9 and at month 12 of treatment=(serum concentrations at month 1, month 3, month 6, month 9 and month 12 - serum concentration at baseline)/serum concentration at baseline\*100%

    Time frame: baseline, at month 1, at month 3, at month 6, at month 9,and at month 12

  4. Proporation of new osteoporotic fractures(vertebrae, total hip and non-vertebrae) occurring within the study period

    Osteoporotic fracture is defined as the fracture occurred when subject suffers minor trauma or during daily activities. Common occurrence sites are vertebral body, hip, distal forearm, proximal humerus and pelvis, etc

    Time frame: baseline, at month 12

  5. Adeverse events and serious adverse events

    Evaluation of the drug reactions, changes in physical examination findings, changes in vital signs, stomatological examination, clinical laboratory testing for systemic safety(including complete blood count, urinalysis, clinical chemistries, coagulation function, liver function, renal function, parathyroid function), and electrocardiography

    Time frame: baseline ,at 12 months

  6. Immunogenicity

    Binding antibody and neutralizing antibody formation assays were used to assess number of subjects with anti-denosumab antibody

    Time frame: baseline, at 12 months

  7. Population pharmacokinetics analysis

    The pharmacokinetic parameters were described statistically, such as population typical value of clearance rate, estimation precision of typical value, confindence interval of typical value, and inter individual variation

    Time frame: baseline, at 12 months

07

Study locations

1 site
  • Peking Union Medical College Hosptial
    Beijing, Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Nov 2024, 43 months.

Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 43 months is above that.

Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2020
First posted
Oct 19, 2020
StartActual
Mar 31, 2021
Primary completionActual
Nov 1, 2024
CompletionActual
Nov 1, 2024
Last update
Feb 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04591275
Lead sponsor
Shanghai Biomabs Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Oct 19, 2020
Start date
Mar 31, 2021
Primary completion
Nov 1, 2024
Completion
Nov 1, 2024
Last update
Feb 20, 2025

Study contacts

weibo Xia, Doctor
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion